Skip to main content
. Author manuscript; available in PMC: 2026 Jul 23.
Published in final edited form as: J Am Acad Child Adolesc Psychiatry. 2025 Jul 23;65(7):917–928. doi: 10.1016/j.jaac.2025.07.421

Figure 1. Changes in attention-deficit/hyperactivity disorder symptom ratings following 12-week psychostimulant treatment.

Figure 1.

Note: Symptom changes are separately shown for (A) ADHD-RS total score, (B) ADHD-RS hyperactivity/impulsivity subscale score and (C) ADHD-RS inattention subscale score. Values are group mean ± SEM. P-values for the group × time interaction are presented, and asterisks indicate significant within-group baseline-endpoint changes. ADHD-RS = attention-deficit/hyperactivity disorder rating scale; HR-MAS = high-risk youth treated with mixed amphetamine salts; LR-MAS = low-risk youth treated with mixed amphetamine salts. SEM = standard error of the mean.

*p < .05, **p < 0.01, ***p < .001.